Format

Send to

Choose Destination
J Child Adolesc Psychopharmacol. 2017 Aug;27(6):546-554. doi: 10.1089/cap.2015.0247. Epub 2016 Sep 8.

Pediatric Antipsychotic Use and Outcomes Monitoring.

Author information

1
1 Department of Child Psychiatry, King's College London , London, United Kingdom .
2
2 Centre for Interventional Pediatric Psychopharmacology and Rare Diseases (CIPPRD) , South London and Maudsley NHS Foundation Trust, London, United Kingdom .

Abstract

Antipsychotic (ATP) prescription rates have increased in children and adolescents despite concern regarding the safety and effectiveness of ATP usage in community populations. Rising safety concerns and uncertainty regarding ATP effectiveness in children stress the need for improvement in routine clinical outcome monitoring and research. Due to the growing number of children exposed to atypical ATPs, studies assessing the risk/benefit ratio of administering ATPs in this age group-especially in off-label conditions-become of high importance. The Centre for Interventional Pediatric Psychopharmacology and Rare Diseases (CIPPRD) uses a suite of instruments to monitor outcomes using the web-based HealthTrackerâ„¢, a health monitoring platform. The HealthTracker allows for capture of symptoms, side effects, quality of life, patient experience, and lifetime response to individualized treatments using a multi-informant multimodal methodology. It enables the tracking of ongoing medical treatments and assists in shared treatment decision-making, longitudinal patient centered outcome monitoring, and helps optimize care. An example of its use in the CIPPRD is provided to demonstrate how it can be used for ATP-related outcome monitoring in complex neurodisability within routine clinical practice.

KEYWORDS:

CIPPRD; antipsychotics; children; monitoring; side effects

PMID:
27607909
DOI:
10.1089/cap.2015.0247
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center